NATCO PHARMA LTD. - 524816 - Shareholding for the Period Ended June 30, 2021
Natco Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here07-07-2021
07-07-2021
NATCO PHARMA LTD. - 524816 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
certificate under Reg 74 (5) of SEBI (DP) Regulatins, 2018 for the quarter ending June 30,202105-07-2021
NATCO PHARMA LTD. - 524816 - Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- M ADINARAYANADesignation :- Company Secretary and Compliance Officer05-07-2021
Hold Natco Pharma; target of Rs 1010: ICICI Direct
ICICI Direct recommended hold rating on Natco Pharma with a target price of Rs 1010 in its research report dated June 18, 2021.21-06-2021
Earnings Call for Q4FY21 of Natco Pharma
Conference Call with Natco Pharma Management and Analysts on Q4FY21 Performance and Outlook. Listen to the full earnings transcript.18-06-2021
Natco Pharma net dips 43% to Rs 53 crore in Q4
Total income during the fourth quarter stood at Rs 360 crore, down from Rs 477 crore in the fourth quarter of the financial year 2019-20, the drugmaker said in a regulatory filing.17-06-2021
Natco Pharma Ltd - 524816 - Audited Financial Results For FY 20-21
Audited Financial Results for FY 20-2117-06-2021
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Q4FY21 Financial Results Earnings Call on 18th June, 202114-06-2021